title: Lymphoma-associated skin cancer: incidence, natural history, and clinical management.
abstract: The link between immunosuppression and skin cancer has been well described. The two most common situations involving immunosuppression-associated skin cancer are solid organ transplantation and non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL). Patients with lymphoma are more likely to have development of a secondary malignancy, with skin cancer being the most common. The most common types of skin cancer in patients with NHL/CLL include melanoma, squamous cell carcinoma, basal cell carcinoma, and Merkel cell carcinoma. Many skin cancers demonstrate increased aggressiveness in patients with NHL/CLL and are associated with higher recurrence rates, increased regional metastasis, and death secondary to skin cancer metastases. This review delineates the current research regarding the relationship between NHL/CLL and cutaneous malignancy. Immunosuppressed patients with skin cancer should be treated promptly and aggressively to decrease recurrence and metastases. Regular skin self-examinations, dermatologic examinations, sun-protective habits, and education may prove beneficial in this high-risk patient population.
authors: Division of Dermatologic Surgery, Mayo Clinic, Rochester, MN, USA.
authors: Jerry D
authors: JD
authors: Brewer
authors: Thomas M
authors: TM
authors: Habermann
authors: Tait D
authors: TD
authors: Shanafelt
mesh_terms: D002280:Basal Cell Carcinoma / Q000453:epidemiology / Q000276:immunology / Q000628:therapy; D015266:Carcinoma, Merkel Cell / Q000453:epidemiology / Q000276:immunology / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000453:epidemiology / Q000276:immunology / Q000628:therapy; D006801:Humans; D015994:Incidence; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000453:epidemiology / Q000276:immunology / Q000628:therapy; D008223:Lymphoma / Q000453:epidemiology / Q000276:immunology / Q000628:therapy; D008545:Melanoma / Q000453:epidemiology / Q000276:immunology / Q000628:therapy; D016609:Neoplasms, Second Primary / Q000453:epidemiology / Q000276:immunology / Q000628:therapy; D012878:Skin Neoplasms / Q000453:epidemiology / Q000276:immunology / Q000628:therapy